180 Wealth Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

180 Wealth Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-227	Closed	-$218K	–	446
2024 Q1	$218K	Buy	+227	New	+$216K	0.04%	355
2022 Q1	–	Sell	-336	Closed	-$209K	–	393
2021 Q4	$209K	Buy	+336	New	+$207K	0.05%	345
2018 Q1	–	Sell	-562	Closed	-$211K	–	246
2017 Q4	$211K	Buy	+562	New	+$228K	0.11%	223

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

180 Wealth Advisors's REGN Position: Q2 2024 in Review

180 Wealth Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q2 2024, closing a stake of 227 shares — an estimated $218K sold.

180 Wealth Advisors first reported a position in REGN in Q4 2017 and held it in 3 quarters. The position peaked at $218K in Q1 2024. 1,334 funds tracked by Wall St. Rank hold REGN as of Q2 2024.

180 Wealth Advisors reported no remaining Regeneron Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
180 Wealth Advisors sold 227 Regeneron Pharmaceuticals shares in Q2 2024, an estimated $218K.
180 Wealth Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2017 and held it in 3 quarters.
180 Wealth Advisors's Regeneron Pharmaceuticals position peaked at $218K in Q1 2024.
1,334 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2024.

Based on 180 Wealth Advisors's 13F filing for Q2 2024, filed 16 Jul 2024.